Vasopharm completes patient enrollment for phase 3 traumatic brain injury trial (NOSTRA)

This article was originally published here

NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic

The post Vasopharm completes patient enrollment for phase 3 traumatic brain injury trial (NOSTRA) appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply